Investment Partners LTD. Sells 13,247 Shares of AbbVie Inc. $ABBV

Investment Partners LTD. reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 76.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,057 shares of the company’s stock after selling 13,247 shares during the period. Investment Partners LTD.’s holdings in AbbVie were worth $939,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of ABBV. Vanguard Group Inc. boosted its stake in AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after purchasing an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Norges Bank acquired a new position in AbbVie during the 2nd quarter worth approximately $4,288,200,000. Finally, Raymond James Financial Inc. lifted its stake in AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ABBV. Morgan Stanley boosted their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Scotiabank initiated coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. Finally, Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $231.57 on Friday. The company’s 50 day moving average price is $223.56 and its 200-day moving average price is $220.85. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a market capitalization of $409.28 billion, a P/E ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.